Research Article
Osimertinib Improves the Immune Microenvironment of Lung Cancer by Downregulating PD-L1 Expression of Vascular Endothelial Cells and Enhances the Antitumor Effect of Bevacizumab
Figure 5
Osimertinib inhibits PD-L1 expression in endothelial cells and inhibits tumor growth. (a) C57BL/6 mice were injected with 1 × 106 B16 cells, and tumors grew. The tumor growth curve of each treatment group (n = 6 per group). (b) Tumor weight in each treatment group. (c) Representative images of immune cell markers (CD8+ T cells) in B16 tumor tissue. (d) Quantification of CD8+ T cells in B16 tumors. (e) Representative images of immune cell markers (FoxP3+ T cells) in B16 tumor tissue. (f) Quantification of FoxP3+ T cells in B16 tumors. (g) Statistics of CD8/FoxP3 ratio in tumor tissue. , .
| (a) |
| (b) |
| (c) |
| (d) |
| (e) |
| (f) |
| (g) |